EUVIMEDEUVIMED entdecken
Crossref

Using Win Odds to Improve Commit‐to‐Phase‐3 Decision‐Making in Oncology

Benjamin F Hartley iD, Thomas Drury iD, Brian Di Pace iD, Helen Zhou, Tai-Tsang Chen iD, Inna Perevozskaya iD

Statistics in Medicine · 2025

DOI: 10.1002/sim.70024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Benjamin F Hartley und 5 weiteren Autor:innen. Beteiligte Einrichtung: Veramed Ltd., Twickenham, UK. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Decision Making, Medical Oncology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: GlaxoSmithKline, GlaxoSmithKline España.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Making good decisions about whether to commit‐to‐phase 3 clinical trials is challenging. This is especially true in oncology because the relationships between the registration endpoint, overall survival, and endpoints such as progression‐free survival and confirmed objective response are often poorly understood. We present a framework for decision‐making based on a three‐endpoint win odds. We discuss properties of the win odds and suggest that it can be interpreted, for decision‐making, as the reciprocal of an average hazard ratio for overall survival. We confirm the performance of the decision‐making method using simulation studies and a clinical trial case study. As part of this work, we describe the simulation of correlated patient‐level oncology endpoints using a multi‐state model of disease. This model can provide clinically realistic data for testing the performance of analysis methods. We conclude that the win odds can improve commit‐to‐phase‐3 decision‐making compared with other methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase III as TopicDecision MakingMedical OncologyHumansComputer SimulationNeoplasmsModels, StatisticalOdds RatioEndpoint Determination

Stichwörter der Autor:innen

multi‐state modelphase 2 clinical trialsquantitative decision makingsurrogate endpointswin statistics

Autor:innen und Institutionen

  • Veramed Ltd., Twickenham, UK.
  • Statistics and Data Science Innovation Hub, GSK Research and Development, Brentford, UK.
  • Oncology Statistics, GSK Research and Development, Collegeville, Pennsylvania, USA.
  • Statistical Methodology, Bristol Myers Squibb, Princeton, New Jersey, USA.

ORCID-Profile: Benjamin F Hartley, Thomas Drury, Brian Di Pace, Tai-Tsang Chen, Inna Perevozskaya

Förderung

  • GlaxoSmithKline
  • GlaxoSmithKline España

Zitieren

APA

Hartley, B. F., Drury, T., Di Pace, B., Zhou, H., Chen, T. T., & Perevozskaya, I. (2025). Using Win Odds to Improve Commit‐to‐Phase‐3 Decision‐Making in Oncology. Statistics in Medicine. https://doi.org/10.1002/sim.70024

Vancouver

Hartley BF, Drury T, Di Pace B, Zhou H, Chen TT, Perevozskaya I. Using Win Odds to Improve Commit‐to‐Phase‐3 Decision‐Making in Oncology. Statistics in Medicine. 2025. doi:10.1002/sim.70024

BibTeX
@article{Hartley2025,
  author = {Hartley, Benjamin F and Drury, Thomas and Di Pace, Brian and Zhou, Helen and Chen, Tai-Tsang and Perevozskaya, Inna},
  title = {Using Win Odds to Improve Commit‐to‐Phase‐3 Decision‐Making in Oncology},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70024}
}
Kostenlos starten →